Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what cost-per-quality-adjusted life-year thresholds NHS England will attach to its assessments of the cost-effectiveness of cancer drugs for the purposes of assessing whether they should be funded through the Cancer Drugs Fund; and if he will make a statement.
NHS England has oversight of the Cancer Drugs Fund.
NHS England has advised that work is currently underway to determine the process for reviewing drugs on its national list of cohort policies and on how best to assess costs in relation to clinical benefit delivered.